Document:

Exhibit 4.19

EXHIBIT 4.19

Global Medical Sciences Inc.

Letter of intent

August 28, 2002

Antonios Kripotos

President 

San Antonios Resources Inc.

Per:

Mr. Lindsay Semple

Suite 536-1489 Marine Drive

West Vancouver

British Columbia, V7T I B8

Sir:

This is to indicate our interest as licensors ("Licensor") to
enter into an exclusive worldwide licensing agreement with San Antonios
Resources Inc. ("GPM Inc.") (name to be changed to Global Precision Medical Inc
before closing) for the licencing of a technology known as the URO stent
technology (the "Technology").

The conditions under which we are prepared to enter into this transaction are
the following.

1. We will on Closing enter into a Technology Licence Agreement with GPM Inc.
providing for an exclusive worldwide licence to commercialize the Technology.

2. In consideration of such Licence Agreement, we shall be issued an equal
number of shares to the common shares which shall be on the books of the Company
at the date of closing, which we understand will be approximately 3,975,000. The
Licence Agreement shall provide that it shall, at our election, become null and
void in the event that GPM Inc. is found to have made a material
misrepresentation. A material misrepresentation shall include, without
limitation: (1) the existence of any undisclosed debt in excess of $25,000; (2)
the breach by GPM Inc. of any law leading to the payment of money or the
incurring of any obligation by GPM Inc. in excess of $25,000; (3) the failure to
comply or the breach of any securities law or requirement, and (4) any reason
preventing GPM Inc. from fully exploiting the Technology.

3. The Licence Agreement shall also provide us with the full opportunity to
conduct a due diligence on GPM Inc. before Closing, which shall include, without
limitation, access to all books and records. To this end, the Investor Group
shall send us within ten (10) business days of the present letter audited
financial statements of GPM Inc. for the past four (2) years as well as Canadian
and U.S. federal, provincial and state tax returns for such years with related
Notices of Assessment or Reassessment and the date of the last tax audits by
Canadian and U.S. federal, provincial and state authorities. This shall include
subsidiaries of GPM Inc..

4. Before Closing, the finance group shall have acquired or shall have the right
to acquire at least 2.800,000 of all existing issued shares of San Antonios
Resources Inc (publicly reported as being 3,073,129) that are issued and
outstanding.

The present letter is subject to our due diligence as to the referenced matters
above.

Signed this 28th day of August, 2002

GLOBAL MEDICAL SCIENCES INC.

Per:

/s/ Boris Weiss 

Boris Weiss - President

SAN ANTONIOS RESOURCES INC.

/s/ Antonios Kripotos 

Antonios Kripotos - PresidentExhibit 4.20

EXHIBIT 4.20

LICENSE AND JOINT PRODUCT DEVELOPMENT AGREEMENT

AGREEMENT, made as of this 23rd of September 2002, between GLOBAL
MEDICAL SCIENCES LTD., a Barbados corporation, having its principal office
in the City of Bridgetown, Barbados (hereinafter called "Licensor", acting for
the present purposes by its agent Zecotek Holdings Inc) and Global Precision
Medical Inc- (formerly San Antonios Resources), a British Columbia corporation
having its principal office in the City of Vancouver, British Columbia, or its
assignee San Antonios Resources (USA) Inc, its wholly-owned subsidiary
("Licensee")

WHEREAS Licensor is the lawful owner of intellectual property rights in a
specified medical device known as the Urethral Stent (the "Stent"), having
acquired these rights from the scientists listed in Appendix A,

WHEREAS Licensor acquired these intellectual property rights for the purpose of
entering into the present joint licensing and development agreement having the
express purpose of allowing the Stent to be taken to market after further
development;

WHEREAS the intent of the parties is that the Licensor be active in all aspects
of the project to eventually take the Stent to market;

WHEREAS Licensee wishes to enter into the present agreement to licence the
Licensor's intellectual property rights in the Stent for the full term of the
patent rights on the Stent, and to provide for the ongoing participation of the
Licensor in further developing the Stent and taking it to market, said present
agreement being made in consideration for the issuance to the Licensor of fully
participating common shares in Licensee;

NOW, THEREFORE, in consideration of the mutual terms and conditions set forth
herein, the parties hereto agree as follows:

ARTICLE I

DEFINITIONS AND INTERPRETATION

1.1         In this Agreement,

a)         "Agreement" shall mean this
Agreement and all instruments supplemental hereto or in amendment or
confirmation hereof, "herein", "hereof', "hereto",

            "hereunder"
and similar expressions mean and refer to this Agreement and not

            to any
particular Article, Section, Subsection or other subdivision-, "Article",

            "Section",
"Subsection" or other subdivision of this Agreement means and

            refers to the
specified Article, Section, Subsection or other subdivision of this

            Agreement.

b)         "Books and Records" shall
mean all books, records, files and documentation

            (in whatever
medium and wherever situated) of the Licensee-, for greater

            certainty,
the phrase "Books and Records" shall include, without limitation, all

 

statements, budgets, projections, books, ledgers, records, financial records,
accounting records, consents, approvals, authorizations, written Contracts. Tax
returns, Employee files, retiree files, insurance policies, Benefit Plans,
documentation, evidence or indication of ownership of the Licensor in and to any
Purchased Asset, all records and correspondence which pertain to its business;

c)         "Closing" shall mean the
cornpletion of the transaction of licence contemplated herein;

d)         "Closing Date" shall mean
September 23, 2002;

e)         "Company" shall mean Global
Medical Sciences Ltd and any subsidiary thereof:

f)         "Improvements" means the
addition to the Stent of characteristics different than than present at of the
Closing Date-,

g)         "Insolvency Event" shall mean
any event where the Company becomes insolvent, bankrupt, or, as a result of a
purported insolvency, is subject to any          
court order having the effect of entrusting its management to a third party
receiver or similar person for the purpose of managing the Company or its
assets,

h)         "Intellectual Property
Rights" shall mean (i) all domestic and foreign Patents, trade marks, trade
names, service marks, copyrights, industrial designs, trade secrets, inventions,
know-how, technology, (ii) all registrations and applications for registration
of intellectual property, and (iii) all ongoing research and development work
undertaken in accordance with Article 2.2,

i)         "Material Event of Default"
shall mean any of the following events which compromises materially the ability
of Licensee to execute on the Permitted Uses of the Stent, and which has not
been remedied by Licensee within thirty (30) davs from the day that Licensor
provides notice to Licensor of such breach:

  
    a)     the breach by Licensee of the
    representations and warranties provided

        herein,

    b)     the Licensee is subject to an Insolvency Event;

    c)     non-performance by the Licensee of its
    obligations;

    d)     the Licensee commences to carry on business in a
    non-medical area

        without the Licensor's consent,

  

j)         "Licence" shall mean the
rights granted to Licensee under the present Licence Agreement;

k)         "Licensed Property", shall
mean the Licensor's Intellectual Property Rights in the Stent;

l)         "Patents" shall mean the
patents and patent pending applications Iisted in Appendix B hereof;

I -

 

m)         "Permitted Countries" shall
mean every country for which Licensee shall have (a) obtained Regulatory
Approval in respect of the Stent and (b) established that, to the best of its
knowledge, the use of the Stent in such country does not violate Intellectual
Property Rights of third parties;

n)         "Permitted Uses" shall mean
the right to manufacture, produce, sell and otherwise commercialize the Stent in
the Permitted Countries, which right shall not however include the right to
grant sub-licences in respect of the Stent except with the Licensor's approval;

o)         "Regulatory Approval" shall
mean the obtention (1) in Canada and the U.S., of a Certificate of Free Sale;
(2) in the European Community, of a "CE Mark" (Conformit6 Europ6enne Mark), and
(3) in other countries of an equivalent authorization to exploit the Stent in
such country,

p)         "Scientists" shall mean the
individuals listed on Appendix A;

q)         "Speciried Consideration"
shall mean the issuance by Licensee of shares representing fifty percent an
equal number of fully participating common shares in its capital stock that are
issued and outstanding immediately before Closing Date;

r)         "Stent" shall mean the device
described in the Patents,

ARTICLE 2

SCOPE OF AGREEMENT

2.1         Licensor presently
grants to Licensee an exclusive worldwide license to use the Licensed Property
in accordance of the Permitted Uses thereof in any        
Permitted Country, in consideration of the Specified Consideration.

2.2         Licensee agrees to so
license the Licensed property provided the Licensor undertakes to continue
actively the further development of the Stent by        
committing to research and development work by the Scientists or a number of
Scientists, as the context may require, by means of ongoing revolving research
and development agreements between the Licensor and the Scientists.
Consideration for such research and development will be paid in accordance with
agreed arm's length terms and will consequently be in addition to the Specified
Consideration. Licensor also agrees to provide management support services on an
active and regular basis to the Licensee.

 

ARTICLE 3

WARRANTIES AND REPRESENTATIONS

Representations and Warranties of the Licensor

3.1         The Licensor
represents and warrants to the Licensee as follows and acknowledges that the
Licensee is relying upon such representations and warranties in connection with
the licence by the Licensee of the Licensed Property and that the Licensee would
not have entered into this Agreement without such representations and
warranties:

a)         Due Incorporation.    
The Licensor:

  
    i)          is
    duly incorporated, validly existing and in good standing under the laws of
    its jurisdiction of incorporation; and

    ii)         has all necessary
    corporate power and authority to own and licence the Licensed Property,

  

b)         Due Authorization.    
The Licensor has the necessary corporate power and authority to execute this
Agreement and to perform its obligations hereunder. The execution of this
Agreement by the Licensor and the performance by the Licensor of its obligations
hereunder has been duly authorized by all necessary action on its part. Such
execution and performance by the Licensor does not require any action or consent
of, any registration with, or notification to, any person, or any action or
consent under any Laws to which the Licensor is subject.

c)         Enforceability.
This Agreement constitutes a legal, valid and binding obligation of the Licensor
enforceable against it in accordance with its terms.

d)         No conflict.
The execution of this Agreement, the consummation of the transactions
contemplated herein, the performance by the Licensor of its obligations
hereunder and the compliance by the Licensor with this Agreement do not:

  
    i)         violate,
    contravene or breach, or constitute a default under, the constating
    instruments or by-laws of the Licensor-,

    ii)         violate, contravene or
    breach, or constitute a default under any contract, agreement, indenture,
    instrument, or commitment to which the Licensor or any Subsidiary may be a
    party, or their properties may be subject, or by which any of them is bound
    or affected:

    iii)         violate, contravene or
    breach any Laws.

  

e)         
Ownership.     The Licensor is the rightful owner of
any and all of the Intellectual Property Rights in the Stent licensed to
Licensee as of the Closing Date and on an ongoing basis as the case may be.

f)         Claims.    
There are no claims, demands or contestations by any person of which the
Licensor is aware that may diminish the value of the Intellectual Property
Rights in the Stent licensed by Licensee.

g)        Third parties.    
The Licensor has obtained any approval required from a third

party to allow it to proceed with this Agreement and to licence the Intellectual

Property Rights in the Stent to Licensee.

 

Representations and Warranties of the Licensee.

3.2         The Licensee
represents and warrants to the Licensor as follows and acknowledges that the
Licensor is relying upon such representations and warranties and that the
Licensor would not have entered into this Agreement without such representations
and warranties:

a)         Due Incorporation.        
The Licensee is duly incorporated, validly existing and in good standing under
the laws of its jurisdiction of incorporation and has   the necessary
corporate power to own or lease its properties and to carry on its business as
such business is presently conducted.

b)         Due Authorization.
The Licensee has the necessary corporate power and authority to execute this
Agreement and to perform its obligations hereunder. The execution of this
Agreement by the Licensee and the performance by the Licensee of its obligations
hereunder have been duly authorized by all necessary corporate action on its
part. Such execution and performance by the Licensee does not require any action
or consent of, any registration with, or notification to, any Person, or any
action or consent under any Laws to which the Licensee is subject,

c)         Enforceability.
This Agreement constitutes a legal, valid and binding obligation of the
Licensee, enforceable against A in accordance with its terms.

d)         No Conflict.
The execution of this Agreement, the consummation of the transactions
contemplated herein, the performance by the Licensee of its obligations
hereunder and the compliance by the Licensee with this Agreement do not violate,
contravene or breach, or constitute a default under, the constating instruments
or by-laws of the Licensee.

e)         No Broker.
Neither the Licensee nor any of its shareholders, directors, officers, employees
or agents has employed or incurred any liability to any broker, finder or agent
for any brokerage fees, finders fees, commissions or other amounts with respect
to this Agreement or any of the transactions contemplated hereby.

f)         No claims.
There are no actions, claims. investigations, arbitrations or other proceedings
(whether or not on behalf of the Licensee) pending or threatened to restrain,
enjoin or invalidate any transaction contemplated by this Agreement, or

 

           
that may in the future materially change the financial position of the Licensee
as of the Closing Date.

g)         Securities compliance.
The Company is in good standing and has fully complied up to the Closing Date
with all obligations and requirements imposed by    any
securities law, regulation and policy statements including, without limitation
that which applies under US securities legislation and any relevant stock
exchange.

 

ARTICLE IV

COVENANTS OF THE LICENSOR

4.1         Intellectual Property
Rights.         The Licensor agrees that
the Licensee may, in its own name, take the necessary steps to file and register
the Intellectual Property Rights that are necessary for the exploitation of the
Stent in any territory in the world.

ARTICLE V

COVENANTS OF THE LICENSEE

5.1         The Licensee shall, on the
Closing Date, deliver to the Licensor at the place of Closing a share
certificate representing the Specified Consideration,

5.2         Ongoing covenants.    
The Licensee shall:

  
    a)         devote
    all of its efforts to exploiting the Stent so as to maximize the Licensee's
    financial returns, which shall include, without limitation, obtaining
    Regulatory Approval for commercialization in every territory where there is
    a material market for the Stent;

    

    b)         in every territory where
    the Licensee shall exploit the Stent, it shall make the required filings and
    registrations to ensure protection of the Licensor's Intellectual Property
    Rights and shall, in this respect, comply with Article IV.

  

ARTICLE VI

SURVIVAL OF REPRESENTATIONS AND WARRANTIES

6.1         The representations and
warranties of the Licensor contained in this Agreement, shall survive the
completion of the transactions contemplated by this          
Agreement.

 

ARTICLE VII

CONDITIONS OF CLOSING

7.1         Conditions for the
Benefit of the Licensee.     This Agreement is
subject to the following conditions, each of which is hereby declared to be for
the exclusive benefit of the Licensee. Each condition is to be performed or
complied with in all respects at or prior to the Closing Date:

  
    a)         
    Truth of Representations-and Warranties of the Licensor. The
    representations and warranties of the Licensor contained in this Agreement
    or in any Schedule annexed hereto or in any certificate or other document
    delivered or given pursuant to this Agreement (considered individually and
    collectively), shall have been accurate in all material respects as of the
    date of this Agreement, and shall be true and correct in all material
    respects as of the Closing Date as though made on such date.

    

    b)         Third Party
    Approvals. There shall have been obtained from all appropriate
    Persons all approvals, consents and assurances, in form and substance
    reasonably satisfactory to the Licensee's legal counsel, necessary in order
    to permit the transactions contemplated herein to be completed without
    affecting or resulting in the termination, cancellation, modification,
    amendment, variation or renegotiation of this Agreement.

    

    c)         No Material Change.
    From the date hereof up to and including the Closing Date, there shall have
    been no material adverse change in the business, operations, properties,
    prospects or condition of the Licensor in connection with the Business and
    the Subsidiaries, nor shall any change of Law have occurred which, in the
    reasonable opinion of the Licensee, materially and adversely affects or may
    materially and adversely affect the Licensor or any Subsidiary.

    

    d)         Litigation.
    There shall be no actions, claims, investigations, arbitrations or other
    proceedings pending or threatened to restrain, enjoin or invalidate any
    transaction contemplated by this Agreement,

  

7.2         Non-complience.       
If any of the conditions of this Section 7.1 has not been satisfied as of the
Closing Date, or if the Licensee is not satisfied for any reason whatsoever with
the results of its due diligence investigation, or if Closing has not occurred
by for reasons other than the Licensee's failure to comply with its obligations
under this Agreement, the Licensee may, at its option, either (i) terminate this
Agreement by notice to the Licensor at any time prior to the Closing without
further formality, or (ii) proceed with the Closing, without prejudice, in
either case, to the Licensee's other rights, recourses and remedies.

7.3         Conditions for
the Benefit of the Licensor.     This Agreement is
subject to the following conditions, each of which is hereby declared to be for
the exclusive benefit of the Licensor. Each condition is to be performed or
complied with in all respects at or prior to the Closing Date.

  
    a)         Truth of
    representations and Warranties of the Licensee.    
    The representations and warranties of the Licensee contained in this
    Agreement or in any certificate or other document delivered or given
    pursuant to this Agreement (considered individually and collectively), shall
    have been accurate in all material aspects as of the date of this Agreement,
    and shall be true and correct in all material respects as of the Closing
    Date as though made on such date.

  

  
    b)         
    Financial Statements and tax returns. The Licensee shall provide,
    for review by the Licensor:

    
      (i)         its
      audited financial statements for the past four fiscal years:

      (ii)        its tax federal and
      provincial income tax returns for the past four years as well as relevant
      notices of assessment and reassessment-,

      (iii)       an opinion from the Company's
      legal counsel certifying that the Company is in good standing in relation
      to applicable corporate and securities laws.

      (iv)       Copy of any contract which, as of
      the Closing Date, binds the Company to pay, after the Closing Date, any
      amount in excess of $1,000.

    

  

7.4         Non-compliance.    
If any of the conditions of this Section 7.3 has not been satisfied as of the
Closing Date, or if the Licensee is not satisfied for any reason whatsoever with
the results of its due diligence investigation, or if Closing has not occurred
by for reasons other than the Licenseds failure to comply with its obligations
under this Agreement, the Licensee may, at its option, either (1) terminate this
Agreement by notice to the Licensor at any time prior to the Closing without
further formality, or (ii) proceed with the Closing, without prejudice, in
either case, to the Licensee's other rights, recourses and remedies.

 

ARTICLE VIII

TERMINATION

8.1     Termination of Licence

  This Licence shall automatically terminate if there is a
  Material Event of Default in which case all rights presently granted to
  Licensee by Licensor by virtue of the present Agreement shall be retroceded to
  Licensor without consideration, effective on the day that Licensor notifies
  Licensee of such breach.

ARTICLE IX

MISCELLANEOUS

9.1     Announcements.    
Prior to Closing, any press release, public announcement or publicity with
respect to the transaction contemplated in this Agreement shall be made only
with the prior written consent of the Parties unless such release, announcement
or publicity is required by Law, in which case the Party required to make such
release, announcement or publicity shall use its best efforts to obtain approval
of the other Party to the form, nature and extent of such disclosure, which
approval shall not be unreasonably withheld, After the Closing, any such press
release, public announcement or publicity by the Licensor shall be made only
with the prior written consent of the Licensee unless such release, announcement
or publicity is required by Law, in which case the Licensor shall use its best
efforts to obtain the Licensee's approval to the form, nature and extent of such
disclosure, which approval shall not be unreasonably withheld. Unless otherwise
determined by a court of competent jurisdiction, the Parties shall keep this
Agreement strictly

confidential and make no disclosure thereof to any person except
the Parties, counsel and advisors and except as may be required in connection
with the consummation of the transactions contemplated hereby or as may be
required by law, without the prior written consent of the other Party,

9.2     Further Assurances.    
Each Party upon the request of the other, whether at or after the Closing, shall
do, execute, acknowledge and deliver or cause to be done, executed, acknowledged
or delivered all such further acts, deeds, documents, assignments, transfers,
conveyances, powers of attorney and assurances as may be reasonably necessary or
desirable to effect complete consummation of the transactions contemplated by
this Agreement.

9.3     Successors In Interest.    
This Agreement and the provisions hereof shall enure to the benefit of and be
binding upon the Parties and their respective successors and assigns. The
Licensor may not assign this Agreement or any of his rights and obligations
hereunder without the prior written consent of the Licensee, The Licensee may
assign this Agreement and all of the Licensee's rights and obligations hereunder
to an affiliate provided however, that such assignment shall not relieve the
Licensee of its obligations hereunder.

9.4     Expenses.       
the Licensor shall bear and pay all costs, expenses and fees (including, without
limitation, legal counsel and accounting fees and disbursements) incurred by the
Licensor in connection with the preparation, execution and consummation of this
Agreement and the transactions contemplated hereunder. The Licensee shall bear
and pay all costs, expenses and fees (including, without limitation, legal
counsel and accounting fees and disbursements) incurred by it in connection with
the preparation, execution and consummation of this Agreement and the
transactions contemplated hereunder,

9.5     Counterparts.    
This Agreement may be executed in one or more counterparts, each of which when
so executed shall be deemed an original, and such counterparts together shall
constitute one and the same instrument.

9.6     Severability.    
Any Article, Section, Subsection or other subdivision of this Agreement or any
other provision of this Agreement which is, or becornes illegal, invalid or
unenforceable shall be severed herefrom and shall be ineffective to the extent
of such illegality, invalidity or unenforceability and shall not affect or
impair the remaining provisions hereof, which provisions shall (a) be severed
from any illegal, invalid or unenforceable Article, Section, Subsection or other
subdivision of this Agreement or any other provision of this Agreement, and (b)
otherwise remain in full force and effect.

9.7     Governing Law.    
This Agreement shall be governed by and interpreted and construed in accordance
with the laws presently in force in the Province of British Columbia.

9.8     Entire Agreement.    
This Agreement, including the Schedules, constitutes the entire Agreement
between the Parties pertaining to the subject matter hereof, and supersedes all
prior agreements, understandings, negotiations and discussions of the Parties.

9.9     Inconsistency.    
This Agreement shall override the Schedules annexed hereto to the

extent of any inconsistency.

9.10     Gender.     Any
reference in this Agreement to any gender shall include both genders and the
neuter, and words herein importing the singular number only shall include the
plural and vice versa.

9.11     Currency.    
All of the dollar amounts mentioned in this Agreement or in the Schedules
annexed hereto shall be in Canadian funds, unless otherwise specifically
denominated

9.12     Headings.    
The headings in this Agreement are inserted for convenience of reference only
and shall not affect the interpretation hereof.

9.13     Amendment.    
No amendment shall be binding unless expressly provided in an

instrument duly executed by the Parties.

9.14     Waiver.    
No waiver, whether by conduct or otherwise, of any of the provisions of this
Agreement shall be deemed to constitute a waiver of any other provisions
(whether or not similar) nor shall such waiver constitute a continuing waiver
unless otherwise expressly provided in an instrument duly executed by the
Parties to be bound thereby.

9.15     For greater certainty, it is provided that,
provided the Licensee has assigned its rights in the letter of intent regarding
the Stent before Closing to San Antonios Resources (USA) Inc., its US
subsidiary, the present agreement shall be read as being made directly with such
US subsidiary as Licensee. Accordingly, Global Precision Medical Inc. shall be
construed to have assigned before Closing only its rights under the letter of
intent and not the present Agreement or any intellectual property rights granted
by the present Agreement.

9.16     Zecotek Holdings Inc. is presently acting as
a agent under a pre-incorporation contract with Global Medical Sciences Ltd. As
soon as possible after Closing, Global Medical Sciences Ltd shall be
incorporated and shall ratify the present Agreement and declare Itself bound by
it as of Closing with the legal effect that the present Agreement shall be
construed as having been concluded on Closing directly with Global Medical
Sciences Ltd. In the event that Global Medical Sciences Ltd. is not incorporated
or does not so ratify the present Agreement, the present agreement shall be
considered to have been concluded with Zecotek Holdings Inc acting as
principal.. Zecotek Holdings presently declares that it has boon given the
authority to so act by the Scientists and to enter into the present Agreement on
this basis and on these conditions.

9.17     Retrocession.    
In the event that the Board of the Licensee resolves to abandon the pursuit of
the Stent Intellectual Property Rights, these rights shall be retroceded to the
licensor without consideration without further claim or right by the Licensee.

IN WITNESS WHEREOF, the Parties have executed this Agreement on the date
and at the place first above mentioned.

Witnesses:

                                                                                                             
 [LICENSOR]

  
    
      
        
          
            
              
                
                  
                    ZECOTEK HOLDINGS INC.

                    Acting as agent under a 

                    Pre-incorporation contract

                    For the benefit of Global Medical

                    Sciences Ltd.

                     

                  

                

              

            

          

        

      

    

  

/s/_Lindsay Semple_____                                                            
Per: /s/ Michel Coderre

Name:                                                                                         
Name: Michel Coderre

                                                                                                   
Title: CEO

[LICENSEE]

/s/ Boris Weiss__________                                                         
Per: _/s/ Lindsay Semple 

Name:                                                                                         
Name: Lindsay Semple

                                                                                                   
Title: CEO

 

APPENDIX A

STENT SCIENTISTS

Kovneristy, July K

Vytoulev, Oleg A.

Goncharenko, Boris A,

Kulapov, Anatoly K

Partosh, Victor T.

Ivanov, Alexei V.

Cherkasov, Valery A.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}]]